Liquidia launches Phase 3 Re-Spire trial of L606 inhaled treprostinil in PH-ILD - LQDA News | RalliesLiquidia launches Phase 3 Re-Spire trial of L606 inhaled treprostinil in PH-ILD
L
LQDA• Phase 3 Re-Spire trial launch and ERS 2026 posters
- Liquidia scheduled two posters on inhaled treprostinil programs for the ERS 2026 Congress in Barcelona on Sept. 5-9, 2026.
- Results have not been presented yet; the posters are set for Sept. 7 and Sept. 8.
- One presentation will outline baseline lung imaging patterns in PH-ILD patients enrolled in the ASCENT study.
- Another will preview the Phase 3 Re-Spire trial design testing L606, a twice-daily extended-release liposomal treprostinil, in PH-ILD.
- The update underscores a push to broaden clinical evidence supporting next-generation inhaled treprostinil options for PH-ILD.
IBEX
•
